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Diagnosis, Evaluation and 
Treatment for Dementia 
John Margraf, MD 
© Lehigh Valley Health Network 
75 y.o. female 
▪ 3 year hx progressive short term memory loss 
▪ 2 years ago stopped driving after she became lost 
▪ Past 1-2 years speech punctuated by pauses to 
find proper word or substituting  inappropriate word 
▪ Past 1-2 years inability to attach names to familiar 
faces 
▪ Past 6-12 months difficulty planning and preparing 
her own meals and eating mostly sweets and ice 
cream 
▪ Gait slowing and shuffling more recently 
▪ Increasing paranoia  
Dementia 
▪ Decline in cognition severe enough to 
interfere with daily life ( social, 
occupational, etc.)  
▪ Represents a decline from previous level 
of function 
▪ No underlying systemic medical cause 
 
Alzheimer’s Facts 
▪ Affects 5 million in U.S ; 17 million worldwide. 
▪ Affects > 30% of persons > 80 y.o. 
▪ 6th leading cause of death in this country and the 
only disease among the 10th deadliest that 
cannot be prevented,  slowed, or cured. 
▪ By the year 2050 estimated to affect 13.5 million 
people in U.S. 
▪ Accounts for 50% of cases of dementia in 
autopsy and clinical series.  





▪ 1st degree relative of a subject with late 
onset AD has 2x the expected risk of 
acquiring the disease. 
▪  Concordance rate in twin studies   
    ( Swedish registry ) :    
   59 % for monozygotic twins 
  35 % for same sex dizygotic twins 
  24 % for opposite sex dizygotic  
  twins                           
 
▪                      
 
AD is pathologically characterized by the presence of 
extracellular amyloid plaques (composed of 
aggregated amyloid-β peptide) and intracellular 
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Typical AD 
▪ Memory loss is first and predominant 
complaint 
 
▪  Associated with a deficit in at least 1 other 
cognitive domain 
 
▪ Absence of early motor features 
Core Elements of Declining  Cognition 
( Domains )   
 
▪ Memory – misplaces things, repeats, forgets 
conversations and appointments  
▪ Speech – expressive speech +/or comprehension 
▪ Behavior and personality ( apathetic, disinhibited, 
argumentative, compulsive, paranoid ) 
▪ Visuospatial – gets lost, difficulty dressing, 
hallucinations 
▪ Executive – inability to make decisions, solve 
problems, complete complex tasks, handle 
gadgets 
Mild Cognitive Impairment 
▪ Concern regarding a decline in cognition 
not severe enough to impact independent 
living 
▪ Often in one cognitive domain only and 
usually affecting memory ( primarily short 
term ) 
▪ Conversion to dementia in 10-15% / year 
▪ MMSE 25-27 
Mild AD 
▪ Decline in 2 or more domains 
▪ Still able to care for self 
▪ Decreased attention  
▪ Difficulty with complex tasks 
▪ Work trouble 
▪ Halting speech 
▪ MMSE 19-24 
▪ Problems at work 
Moderate AD 
▪ Worsening memory, confusion, 
disorientation 
▪ Appearance of behavioral symptoms, 
wandering, restlessness 
▪ Increasing aphasia 
▪ More difficulty with ADLs 
▪ Unable to be left alone 
▪ MMSE 10-18 
Advanced AD 
▪ Total dependency for ADLs 
 
▪ Worsening behavior and gait progressing 
to bed and wheelchair existence 
Subtypes of Alzheimer’s Disease 
▪ Typical 
▪ Hippocampal sparing 
▪ Hippocampal predominant 
▪ Clinical sx and patterns of atrophy on 
MRI parallel density and distribution of 
NFTs 
Dementia- Etiologies 
▪ Alzheimer’s disease 
▪ Vascular Dementia 
▪ Fronto-Temporal Lobar Dementia 
▪ Lewy Body Disease 
▪ Normal Pressure Hydrocephalus 
▪ Others 
Dementia: role of MRI updated version 
Frederik Barkhof, Marieke Hazewinkel, Maja Binnewijzend 
and Robin Smithuis 
Alzheimer Centre and Image Analysis Centre, Vrije 
Universiteit Medical Center, Amsterdam and the Rijnland 
Hospital, Leiderdorp, The Netherlands 
 




▪ Stepwise progression of symptoms 
secondary to recurrent strokes 
▪ Gradual progression of symptoms due to 
subclinical ischemia and progressive 
accumulation of “ non specific T2 white 
matter hyperintensities “ 
▪ Often coexists with Alzheimer’s pathology 
Frontotemporal Dementia –  
3 Major Subtypes 
▪ Prominent behavioral change and 
disordered social conduct 
▪ Progressive nonfluent aphasia 
▪ Impaired understanding of word 
meaning and/or object identity 
Frontotemporal Dementia 
▪ Memory and visuospatial skills relatively 
preserved early 
▪ Pathology – Pick bodies and other various 
neuronal and glial inclusions 
▪ Onset often before age 65. 
▪ Some cases exhibit autosomal dominant 
inheritance 
▪ Minority have co-existent motor neuron 
disease 
Divorced 60 y.o female – live alone 
▪ 2 years ago fired from her job as dental 
assistant 
▪ Family concerned because she is 
frequenting bars late at night – never did 
this before 
▪ Has become obsessed with getting back 
with husband 
▪ Beginning to have word finding problems 







Diffuse Lewy Body Disease 
▪ Impairment in memory, attention,  
executive function and visuospatial ability 
▪ Parkinsonism 
▪ Visual hallucinations 
▪ Fluctuating cognition with pronounced 
variations in attention and alertness 
▪ Pathology- Lewy bodies ( intraneuronal 
cytoplasmic inclusions containing alpha- 
synuclein ) 
69 y.o. Innkeeper 
▪ 9 months ago family noticed he seemed 
confused while on a cruise. 
▪ confusion has worsened since 
▪ Has started to see imaginary people on 
property next door 
▪ No longer can plan meals 
▪ Up at night wandering 
▪ Gait has noticeably slowed and he is 
starting to shuffle 
 
Normal Pressure Hydrocephalus 
▪ Ataxia 
 





Rapidly Progressive Dementia   
( weeks to months ) 









▪ Hx from pt and informant- review  drug list  
▪ PE including cognitive testing 
▪ Screen for depression 
▪ CBC, CMP, TSH,B12 
▪ Brain image- CT or MRI 
▪ Consider LP if rapidly progressive 
▪ Consider neuropsych testing 
▪ Consider EEG if ? seizures or CJD 
▪ Consider PET scan 
 
History 
▪ Start with the onset of the first cognitive 
symptom then develop a detailed 
description for the evolution of all 
subsequent areas  of cognitive decline 
 
▪ Query all domains 
 
▪ History from patient and informant 
   
Core Elements of Declining  Cognition 
( Domains )   
 ▪ Memory – misplaces things, repeats, forgets 
conversations and appointments  
▪ Speech – expressive speech +/or comprehension 
▪ Behavior and personality ( apathetic, disinhibited, 
argumentative, compulsive, paranoid ) 
▪ Visuospatial – gets lost, difficulty dressing, 
hallucinations 
▪ Executive – inability to make decisions, solve 
problems, complete complex tasks, handle 
gadgets 
Alzheimer's Association recommendations for 
operationalizing the detection of cognitive 
impairment during the Medicare Annual Wellness 
Visit in a primary care setting 
Alzheimer’s & Dementia - (2013) 1–10 








American Journal of Geriatric Psychiatry:  
May 2006 - Volume 14 - Issue 5 - pp 391-400 
What Is the Best Dementia Screening Instrument for 
General Practitioners to Use ? 
Brodaty, Henry M.B.B.S., M.D., F.R.A.C.P., F.R.A.N.Z.C.P.; 
Low, Lee-Fay B.Sc.(Psych.)Hons.; Gibson, Louisa B.Sc.(Arch.), 




Other Cognitive Tests 
▪ Mini Mental State- copyright restricted , 
relatively insensitive to mild cognitive 
impairment and non AD dementias 
 
▪ Montreal Cognitive Assessment- more 
sensitive for frontal-executive function 
   
▪ St Louis University Mental Status 
Examination ( SLUMS) 
Neuropsychological Testing 
▪ Labor intensive and relatively expensive 
but useful  in certain settings ( ex. early or 
young onset ) 
MRI and/or CT Brain 
▪ R/O treatable pathology 
 
 










Central and Cortical Atrophy 
Hippocampal Atrophy 
Frontotemporal Dementia 
Effectiveness of Cholinesterase Inhibitors and 
Memantine for Treating 
Dementia: Evidence Review for a Clinical Practice 
Guideline 
 
Parminder Raina, PhD; Pasqualina Santaguida, 
PhD; Afisi Ismaila, MSc; Christopher Patterson, 
MD; David Cowan, MD; Mitchell Levine, MD; 
Lynda Booker, BSc; and Mark Oremus, PhD 
Ann Intern Med. 2008;148:379-397. 
Conclusions: Treatment of dementia with cholinesterase 
inhibitors and memantine can result in statistically 
significant but clinically marginal improvement in measures 
of cognition and global assessment of dementia. 
Cholinesterase Inhibitors and 
Memantine 
▪ Does the medication improve my patient’s 
quality of life ? 
▪ Is the improvement worth the cost ? 
▪ What about side effects ? ( G.I., 
nightmares ? ) 
 
Syncope and Its Consequences in Patients 
With Dementia Receiving Cholinesterase Inhibitors 
A Population-Based Cohort Study 
Sudeep S. Gill, MD, MSc; Geoffrey 
M. Anderson, MD, PhD; Hadas D. 
Fischer, MD; Chaim M. Bell, MD, 
PhD; Ping Li, PhD; Sharon-Lise T. 
Normand, PhD; Paula A. Rochon, 
MD, MPH 
ARCH INTERN MED/VOL 169 (NO. 9), MAY 11, 
2009 
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Dementia Performance 
Measurement Set 
▪ Staging of dementia 
▪ Cognitive assessment 
▪ Functional status assessment 
▪ Neuropsychiatric symptom assessment 
▪ Management of neuropsychiatric symptoms 
▪ Screening for depressive symptoms 
▪ Counseling regarding safety concerns 
▪ Counseling regarding risks of driving 
▪ Palliative care counseling and advance care 
planning 
▪ Caregiver education and support 
 
Pharmacological Treatment 
of Neuropsychiatric Symptoms of Dementia 
A Review of the Evidence 
 
Kaycee M. Sink, MD 
Karen F. Holden, MD 
Kristine Yaffe, MD 
JAMA, February 2, 2005—Vol 293, No. 5 
Alz.org 
▪ Cognitive and informant assessment 
tools 
▪ Diagnostic guidelines and suggested w/u 
▪ 7 stages of Alzheimers 
▪ Differential dx with links to other 
degenerative disease sites 
▪ Section on managing challenging 
behaviors  
▪ Links to clinical studies 
Dominantly Inherited 
Alzheimer’s Network ( DIAN ) 
 
 
▪ Worldwide network of autosomal dominant 
Alzheimer’s disease centers 
Original Article
Clinical and Biomarker Changes in Dominantly 
Inherited Alzheimer's Disease
Randall J. Bateman, M.D., Chengjie Xiong, Ph.D., Tammie L.S. Benzinger, M.D., 
Ph.D., Anne M. Fagan, Ph.D., Alison Goate, Ph.D., Nick C. Fox, M.D., Daniel S. 
Marcus, Ph.D., Nigel J. Cairns, Ph.D., Xianyun Xie, M.S., Tyler M. Blazey, B.S., 
David M. Holtzman, M.D., Anna Santacruz, B.S., Virginia Buckles, Ph.D., Angela 
Oliver, R.N., Krista Moulder, Ph.D., Paul S. Aisen, M.D., Bernardino Ghetti, M.D., 
William E. Klunk, M.D., Eric McDade, M.D., Ralph N. Martins, Ph.D., Colin L. 
Masters, M.D., Richard Mayeux, M.D., John M. Ringman, M.D., Martin N. 
Rossor, M.D., Peter R. Schofield, Ph.D., D.Sc., Reisa A. Sperling, M.D., Stephen 
Salloway, M.D., John C. Morris, M.D., for the Dominantly Inherited Alzheimer 
Network
N Engl J Med
Volume 367(9):795-804
August 30, 2012
Clinical and Biomarker Changes in 
Dominantly Inherited Alzheimer’s 
Disease 
▪ Concentration of amyloid in CSF begins to 
decline 25 years before expected onset of sx. 
▪ amyloid beta detected by PET ( PiB ) 15 years 
before. 
▪ Increase  in CSF tau and atrophy on MRI 15 
years before. 
▪ Cerebral hypometabolism ( FDG PET ) and 
impaired episodic memory 10 years before 
▪ Global cognitive impairment 5 years before 
  Alzheimer  1864-1915 
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Resources 
▪ Caregiver & Family Resources 
• Alzheimer’s Association 
– Multiple sources of assistance 
– 24/7 Helpline 1-800-272-3900 
• Knowing the signs of caregiver stress 
• Respite Care 
– Private Duty Agencies 
– Assisted Living for overnight stays 




• Driving Evaluations to assess competency 
– Good Shepherd  
– Ph: 610-776-3517, Fax: 610-776-8375 
• Power of Attorney & Living Will 
• In-home help 
– Referral to County Aging office if over 60 
– Lehigh County: 610-782-3034 
– Northampton County: 610-559-3270 
 
Down’s Syndrome and AD 
▪ 1929 -  senile plaques noted in brains of relatively young subjects. 
 
▪ 1948 - some patients with Down’s syndrome noted to develop 
Alzheimer type dementia in their 30’s and 40’s. 
 
▪ 1958 - Down’s syndrome associated with extra copy of chromosome 
21. 
 
▪  mid 1980‘s   Woman in Nottingham England alerts Al;zheimer’s 
researcher at St. Mary’s Hospital in London to high incidence of AD 
in her father’s family. Mutated gene found to reside on chromosome 
21 
 
▪ 1987 – gene for amyloid precursor protein linked to chromosome 21 
 
